Fresh analysis reveals that people who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt conventional diet and exercise programs.
Published data in a major health publication shows that while obese individuals frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"People using such drugs need to be cognizant of the risk of rapid rebound weight gain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment mass in about one and a half years.
Analyzing Approaches
The study, which reviewed dozens of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through dieting generally experience a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Nutrition scientists believe the way of the jabs explains the amplified weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication means hunger is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
The NHS recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, given the likelihood of relapse, the therapy might need to be long-term.
This view is echoed by pharmaceutical companies, who state that the results "emphasize the persistent nature of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Users who have stopped the jabs explain a sudden return of cravings.
"It felt as if something activating and you become ravenous," recalled a patient.
The struggle is compounded if patients have not developed permanent lifestyle or habit modifications during therapy.
Widespread Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while the jabs are potent agents for shedding pounds, they are not a permanent fix and lasting health benefits relies on combined behavioural changes.
